A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Sponsor: Novartis Pharmaceuticals
This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia and is currently completed. Novartis Pharmaceuticals leads this study, which shows 17 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 12 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Completed PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Completed PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augusta, United States , Bangkok, Thailand , Barcelona, Spain , Basel, Switzerland , Bobigny, France , Boston, United States , Bruges, Belgium , Budapest, Hungary , Charleston, United States , Cleveland, United States and 26 more locations